For the quarter ending 2025-09-30, CV had $16,709K increase in cash & cash equivalents over the period. -$5,678K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,921 | -10,000 |
| Depreciation and amortization | 54 | 107 |
| Loss on disposal of property and equipment | -1 | - |
| Amortization of operating lease right-of-use assets | 89 | 171 |
| Unrealized foreign exchange gains | 12 | 158 |
| Stock in lieu of debt repayment | 31 | - |
| Stock-based compensation | 307 | 322 |
| Bad debt expense | 0 | 11 |
| Accounts receivable | 16 | -167 |
| Inventory | 145 | 413 |
| Prepaid expenses and other current assets | -636 | 939 |
| Other long-term assets | 0 | 0 |
| Accounts payable | 188 | 408 |
| Accrued expenses and other current liabilities | 1,201 | 1,019 |
| Deferred revenue | 9 | -35 |
| Operating lease liabilities | -88 | -172 |
| Net cash used in operating activities | -5,666 | -9,512 |
| Purchases of property and equipment | 12 | 70 |
| Net cash used in investing activities | -12 | -70 |
| Proceeds from issuance of series h convertible preferred stock | 0 | - |
| Proceeds from ipo, net of commissions | 26,557 | - |
| Payment of deferred ipo offering costs | 3,184 | - |
| Proceeds from promissory note issuance | 0 | 1,000 |
| Repayment of promissory note | 1,000 | - |
| Proceeds from exercises of options on common stock and warrants | 216 | 202 |
| Net cash provided by financing activities | 22,387 | 1,202 |
| Net increase (decrease) in cash and cash equivalents | 16,709 | -8,380 |
| Effect of exchange rate changes on cash | 139 | - |
| Cash and cash equivalents at beginning of period | 9,319 | - |
| Cash and cash equivalents at end of period | 17,787 | - |
CapsoVision, Inc (CV)
CapsoVision, Inc (CV)